icon-folder.gif   Conference Reports for NATAP  
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials
  AASLD 2013 Nov 1-4 Wash DC
Ira M Jacobson,1 Gregory J Dore,2 Graham R Foster,3 Michael Fried,4 Michael Manns,5 Patrick Marcellin,6 Fred Poordad,7 Evaldo Stanislau Affonso de Araujo,8 Monika Peeters,9 Oliver Lenz,9 Sivi Ouwerkerk-Mahadevan,10 Guy De La Rosa,11 Ronald Kalmeijer,12 Rekha Sinha,9 Maria Beumont-Mauviel9
1Weill Cornell Medical College, New York, NY, USA; 2The Kirby Institute, University Of New South Wales, Darlinghurst, Australia; 3Queen Mary's,University of London, London, UK; 4University of North Carolina at Chapel Hill, NC, USA; 5Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; 6Hopital Beaujon, Service d'Hépatologie, INSERM U-481, 100 Boulevard du Général Leclerc, 92110, Clichy, France; 7Texas Liver Institute, University of Texas Health Science Center, 607 Camden St, San Antonio, TX 78215, USA; 8Hospital das Clinicas of the University of Sao Paulo School of Medicine, Faculty of Medicine, University of Sao Paulo, Avenida Dr. Eneas de Carvalho Aguiar, Cerqueira Cesar, 05403-000, Sao Paulo, SP, Brazil; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Jansssen Research & Development, Beerse, Belgium; 11Janssen Global Services, LLC, Raritan, NJ, USA; 12Janssen Research & Development, LLC, Titusville, NJ, USA.